Researchers found that genetic imbalances on chromosomes 8 and 18 were better predictors of colorectal cancer prognosis than conventional assessments. The study used a new approach to investigate chromosome imbalances in early-stage cancers, with patients experiencing varying disease-free survival rates based on their tumour balance.
Researchers found that aspirin does not reduce costs and increase life expectancy for colorectal cancer prevention. Regular screening tests remain highly effective and cost-effective, even for patients taking aspirin for other reasons.
Researchers found that aspirin is not cost-effective addition to national strategy for reducing death from colorectal cancer. Screening methods, such as flexible sigmoidoscopy and yearly fecal occult blood testing, remain highly effective and cost-efficient options.
Screening for colorectal cancer could lead to a 20% reduction in mortality rates, but its effectiveness depends on various factors. The UK government has set up pilot centres to evaluate the potential of faecal occult blood testing (FOBT) as a screening method.
A systematic overview of 22 trials found that preoperative radiotherapy reduces local recurrences by half compared to surgery alone, with a third reduction in postoperative radiotherapy. Fewer patients who received preoperative radiotherapy died from rectal cancer, but early deaths increased.
A study of 2,437 HIV-infected adults found that patients with case managers had fewer unmet needs and higher use of HIV medications. Screening for hereditary colorectal cancer has been shown to work and may be cost-effective, particularly for relatives of affected individuals.
Researchers Dorret Boomsma, Hans Clevers, Bert Meijer, and Hans Oerlemans were awarded for their pioneering work in human behavioural genetics, the discovery of cancer causes, molecular architecture, and icecap dynamics. Their findings have significant implications for our understanding of intelligence, anxiety, and climate change.
A five-year research project investigates the quality of life of older adult long-term cancer survivors, revealing that while cancer can affect their identity and relationships, it does not fundamentally change who they are. Many survivors report positive family dynamics and hope for the future after treatment.
Research suggests that bowel cancer screening strategies targeting solely individuals with a family history may have limited impact on reducing mortality from colorectal cancer. In fact, the study found that around 85% of bowel cancers develop in people without a family history, highlighting the need for more widespread screening.
Researchers discover bacterial toxin ST can slow down metastatic colorectal cancer tumor growth by targeting GCC receptor. GCC is a protein marker on cancer cells that allows scientists to detect if they have spread, and it can also be used as a diagnostic tool.
A genetic defect in the alpha-1 antitrypsin gene is associated with a threefold increased risk of developing sporadic colorectal cancer. Carriers who smoke have a significantly higher risk of developing this type of cancer compared to non-smokers.
Mayo Clinic researchers developed a new, non-invasive DNA test that detected 91% of colorectal cancers and 73% of polyps. The test shows promise for reducing unnecessary colonoscopies and costs associated with colorectal cancer screening.
A mathematical model suggests that one-time colonoscopy at age 55 can significantly reduce colorectal cancer mortality. The study found that this strategy is cost-effective and can achieve up to 50% reduction in CRC mortality, depending on compliance.
A University of North Carolina at Chapel Hill study found that regular garlic consumption reduces stomach cancer risk by half and colorectal cancer risk by two-thirds. The researchers pooled data from 22 studies worldwide to confirm the protective effect, but note that supplements may not be as effective.
Researchers at Memorial Sloan-Kettering Cancer Center developed a new combination therapy of irinotecan, fluorouracil, and leucovorin that nearly doubled the tumor response rate and improved overall survival for patients with metastatic colorectal cancer. The study showed significant benefits with no increased incidence of serious side...
Researchers at Mayo Clinic have discovered a new gene, AXIN2, linked to colorectal cancer development. Mutations in this gene elevate Beta-catenin levels, contributing to the disease.
A study analyzing data from 28 countries found that a diet rich in olive oil was associated with a decreased risk of bowel cancer. The researchers discovered that meat and fish consumption, particularly high amounts, increased the risk of the disease, whereas cereal and vegetable intake had a protective effect.
Researchers have discovered a protein called p110g that suppresses colorectal cancer growth in mice and human cell cultures. The absence of the protein leads to spontaneous development of colorectal cancer, while its presence stops tumour growth.
A genetic program has been identified that constructs the pipeline supplying blood and nutrients to colorectal tumors. This program involves a group of 46 genes known as tumor endothelial markers (TEMs), which are elevated tenfold or more in tumor endothelium.
A UCSD researcher has been awarded a grant to study the incidence and impact of microsatellite instability on colon cancer in African-Americans. The research aims to understand why African-Americans have a higher death rate from colorectal cancer despite lower incidence rates.
Researchers identify genetic abnormalities in microsatelite instability (MSI) and chromosomal instability (CSI) leading to varying tumor behaviors. Colorectal cancer patients with MSI form have a better chance of surviving longer, prompting potential changes in treatment strategies.
A new treatment approach combining traditional chemotherapy with medication delivered through an implanted pump has been found to significantly increase two-year survival rates and decrease tumor recurrence in patients with advanced colorectal cancer that has spread to the liver. The study, published in the New England Journal of Medic...
A new molecular biology test detected a substance in lymph nodes that may indicate future recurrence of colorectal cancer. The American College of Physicians-American Society of Internal Medicine also cautions physicians about selling products from their offices, emphasizing the need for high ethical standards.
Researchers at Thomas Jefferson University have developed a blood test to detect the spread of colorectal cancer to lymph nodes by identifying the presence of a protein called GCC. This test may help doctors diagnose the disease more accurately and provide better treatment options for patients.
Hereditary colorectal cancer tumors with high microsatellite instability (MSI) levels show a lack of genes responsible for DNA mismatch repair, vital to DNA replication. This can lead to faulty repair and colon cancer development.
A study by researchers at Ohio State University found that genes involved in detoxifying cancer-causing chemicals play a role in the development of colorectal tumors. People with certain genetic mutations tend to develop tumors at younger ages or in the distal area of the large intestine.
Researchers at Memorial Sloan-Kettering Cancer Center found nearly 20% of young patients with colorectal cancer have the HNPCC syndrome, a dominantly inherited disorder that increases lifetime risk of developing multiple cancers. Individuals with HNPCC require special surveillance to protect against additional cancers.
A multi-centered study led by Dartmouth Medical School found that supplementation with calcium can reduce the recurrence rate of large bowel adenomas in people with a history of these particular polyps. The findings suggest promising measures that are fairly simple and inexpensive to help prevent colorectal cancer.
A multi-disciplinary team at CWRU will examine the quality of life for cancer survivors aged 60+, exploring coping mechanisms and support systems. The five-year longitudinal study aims to understand how cancer survivors cope with age-related health issues.
Researchers at UT Southwestern Medical Center have developed an animal model for human colorectal cancer, which will facilitate research into the molecular mechanisms of the disease. The model, based on a colon cancer mouse, allows for testing of chemoprevention agents and new drug treatments.
Scientists found that aspirin suppresses accumulation of genetic mutations causing hereditary colorectal cancer. Aspirin screens for cells with stable genetics, potentially preventing the disease. Researchers now plan a clinical trial to study higher doses of aspirin in preventing hereditary colon cancer.
The Seattle Gastrointestinal Program Project will investigate the role of oxidative damage in pancreatitis and chronic ulcerative colitis. Researchers aim to develop screening tests for pancreatic cancer and more sensitive early detection methods for colon cancer.
A study published in Nature Medicine suggests that the diabetes drug troglitazone may increase the risk of colon cancer by activating the PPAR receptor, which promotes tumor formation in the colon. The study found that mice treated with troglitazone developed a significantly greater number of colon polyps than those not treated.
A new study finds that positron emission tomography (PET) can detect additional tumors in patients with warning signs of colorectal cancer. PET imaging confirmed disease in 15 out of 17 patients with tumors, while those with negative results remained cancer-free for at least nine months.
Researchers found that relatives of individuals with colon polyps have a slightly less than doubling of risk compared to the general population, rising to about 10-12% over a lifetime. The study suggests that these individuals should receive colonoscopy instead of sigmoidoscopy for screening.
Researchers at The Wistar Institute have identified a key role for the GA733 antigen in inhibiting colorectal cancer cell invasion. The discovery has led to the development of an antibody that increases survival rates for CRC patients.
Researchers at Rockefeller University are conducting a study to examine the potential of three plant-derived compounds - curcumin, rutin, and quercetin - to prevent colorectal cancer. The study aims to determine whether these compounds can safely inhibit the development of colon polyps and reduce cancer risk.
Researchers at Roswell Park Comprehensive Cancer Center found that p53 mutation does not trigger cancer development for colorectal cancer, contrary to long-held dogma. Instead, they identified a mysterious enigma controlling cell progression to cancerous states.
A new drug, CPT-11, has been approved by the FDA for treating colorectal cancer. Researchers plan to enroll approximately 660 patients in a Phase III trial to evaluate its effectiveness as a first-line treatment.